anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Primary congenital glaucoma (PCG) is one of the leading causes of visual damage and blindness, severely affecting the quality of life of affected children. It is characterized by cupping of the optic disc and loss of ganglion cells due to elevated intraocular pressure. While most PCG patients exhibit epiphora, photophobia, and buphthalmos with corneal opacity, variability in phenotypic manifestations is not uncommon. Prompt diagnosis and treatment of PCG affected individuals becomes relevant to preserve visual function throughout their lives. Most PCG cases are sporadic or autosomal recessive; however, an incompletely dominant autosomal dominant form arising from mutations in the TEK gene has recently been demonstrated. Here, we describe the clinical and mutational features of a cohort of Mexican patients with TEK-related PCG. Our results support the involvement of the TEK gene as an important cause of the disease in our ethnic group and expand the mutational spectrum causing PCG by reporting 10 novel disease-causing variants.
Alopecia areata (AA) is a common autoimmune disease resulting from immune destruction of the hair follicle and subsequent hair loss. Despite its high prevalence, research into the pathogenesis and the development of innovative therapies in AA has lagged far behind other autoimmune diseases. Currently, there are no FDA approved drugs for AA. Ruxolitinib (Incyte) is an intervention known to effectively treat myelofibrosis and also rheumatoid arthritis by modulating the inflammatory response of the interferon response pathway by inhibition of Jak1/Jak2. Rheumatoid arthritis shares several susceptibility genes in common with AA. All three diseases share the central role of the interferon-gamma response pathway, which is the rationale for selecting Ruxolitinib for evaluation in this clinical trial. Both systemic and topical Ruxolitinib have been shown to prevent the onset of AA in the C3H-HeJ animal model of AA, demonstrating preclinical proof-of-concept data in AA. To test the safety and efficacy of Ruxolitinib in patients with moderate to severe AA, we propose this open-label, single arm pilot study with a total of 12 patients, treated for a minimum of 3 months up to 6 months. Efficacy will be measured by changes in hair re-growth as determined by physical exam and photography, as well as by patient and physician global evaluation scores. Patients will be followed for another 3 months to evaluate durability of response following the treatment phase. Punch biopsies and peripheral blood will be obtained at baseline prior to treatment and then after 12 and possibly 24 weeks for immune monitoring and for molecular studies.
Double-blind, randomized, 6-period cross-over study in 16 healthy subjects. Each patient participates in 6 euglycemic glucose clamp experiments each.

The time interval between the study days is 2 to 28 days. At the clamp visits, subjects are connected to a Biostator (MTB Medizintechnik, Ulm, Germany) and receive an intravenous human insulin infusion (rate of 0.15 mU/kg/min) over the duration of each experiment to prevent a rise in endogenous insulin secretion. After a baseline period of 2 h the trial drug (6, 12, or 24 U of either Insulin Aspart or regular human insulin in random order) are administered s.c. with a syringe into the abdominal wall. Glucose infusion rates (GIR) necessary to keep blood glucose concentrations close to the clamp level of 90 mg/dl (5 mmol/l) are administered and recorded by the Biostator every minute for a period of 12 h post-dosing. Blood samples are drawn at regular intervals for the analysis of C-peptide and (depending on the trial drug administered) serum insulin or serum Insulin Aspart concentrations (measured with specific ELISAs).
The metabolic syndrome (MetS) is a multiplex modifiable risk factor for cardiovascular disease, type 2 diabetes mellitus and other health outcomes, and is a major challenge to clinical practice and public health. The rising global prevalence of MetS, driven by urbanization, sedentary lifestyles and dietary changes, underlines the urgency of addressing this syndrome. We explore the complex underlying mechanisms, including genetic predisposition, insulin resistance, accumulation of dysfunctional adipose tissue and ectopic lipids in abdominal obesity, systemic inflammation and dyslipidaemia, and how they contribute to the clinical manifestations of MetS. Diagnostic approaches vary but commonly focus on abdominal obesity (assessed using waist circumference), hyperglycaemia, dyslipidaemia and hypertension, highlighting the need for population-specific and phenotype-specific diagnostic strategies. Management of MetS prioritizes lifestyle modifications, such as healthy dietary patterns, physical activity and management of excess visceral and ectopic adiposity, as foundational interventions. We also discuss emerging therapies, including new pharmacological treatments and surgical options, providing a forward-looking perspective on MetS research and care. This Primer aims to inform clinicians, researchers and policymakers about MetS complexities, advocating for a cohesive, patient-centred management and prevention strategy. Emphasizing the multifactorial nature of MetS, this Primer calls for integrated public health efforts, personalized care and innovative research to address this escalating health issue.
The invention discloses a traditional Chinese medicine pill of a brain-benefiting and marrow-supplementing pill, which is prepared from the following components in part by weight: the invention relates to a Chinese medicinal composition which is prepared from 8 Chinese medicinal herbs including poria with hostwood, orange and Chinese wolfberry, dodder seed, black peach flesh, broomrape, Chinese yam, root of red rooted saliva and mint. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has effects in relieving insomnia, amnesia, preventing depression, delaying physiological and pathological brain atrophy, nourishing marrow and sea, and improving intelligence. 4. Has anti-stress effect, and can increase marrow sea and resist brain failure.
We define a subset of macrophages in the tumor microenvironment characterized by high intracellular iron and enrichment of heme and iron metabolism genes. These iron-rich tumor-associated macrophages (iTAMs) supported angiogenesis and immunosuppression in the tumor microenvironment and were conserved between mice and humans. iTAMs comprise two additional subsets based on gene expression profile and location-perivascular (pviTAM) and stromal (stiTAM). We identified the endothelin receptor type B (Ednrb) as a specific marker of iTAMs and found myeloid-specific deletion of Ednrb to reduce tumor growth and vascular density. Further studies identified the transcription factor Bach1 as a repressor of the iTAM transcriptional program, including Ednrb expression. Heme is a known inhibitor of Bach1, and, correspondingly, heme exposure induced Ednrb and iTAM signature genes in macrophages. Thus, iTAMs are a distinct macrophage subset regulated by the transcription factor Bach1 and characterized by Ednrb-mediated immunosuppressive and angiogenic functions.
The incidence of papillary thyroid cancer (PTC) has been steadily rising, though the underlying mechanism remains unclear. This study aims to elucidate the biological role of TM4SF4 in the PTC progression. Our differential expression analysis indicated that TM4SF4 was significantly upregulated in PTC, which was corroborated in both our local cohort and the data from Human Protein Atlas. Additionally, clinical characteristics analysis and receiver operating characteristic curves (ROC) demonstrated that TM4SF4 served as a significant diagnostic marker for PTC. Correlation and enrichment analysis of TM4SF4-related partners suggested that it was involved in cell junction and cohesion processes. Furthermore, immune infiltration analysis revealed a positive correlation between TM4SF4 expression and the immune activation in PTC. Importantly, in vitro experiments demonstrated that TM4SF4 downregulation suppressed the proliferation and metastasis of PTC cell lines while inducing apoptosis. We further discovered that the AKT activator SC79 was able to reverse the malignant behaviors suppression caused by TM4SF4 knockdown, suggesting that TM4SF4 may promote PTC progression via the AKT pathway. In conclusion, our study highlights the oncogenic role of TM4SF4 in PTC and identifies it as a novel biomarker for diagnosis and treatment.
Previous research has found that an adaptive response to ferroptosis involving glutathione peroxidase 4 (GPX4) is triggered after intracerebral hemorrhage. However, little is known about the mechanisms underlying adaptive responses to ferroptosis. To explore the mechanisms underlying adaptive responses to ferroptosis after intracerebral hemorrhage, we used hemin-treated HT22 cells to mimic brain injury after hemorrhagic stroke in vitro to evaluate the antioxidant enzymes and performed bioinformatics analysis based on the mRNA sequencing data. Further, we determined the expression of GSTO2 in hemin-treated hippocampal neurons and in a mouse model of hippocampus-intracerebral hemorrhage (h-ICH) by using Western blot. After hemin treatment, the antioxidant enzymes GPX4, Nrf2, and glutathione (GSH) were upregulated, suggesting that an adaptive response to ferroptosis was triggered. Furthermore, we performed mRNA sequencing to explore the underlying mechanism, and the results showed that 2234 genes were differentially expressed. Among these, ten genes related to ferroptosis (Acsl1, Ftl1, Gclc, Gclm, Hmox1, Map1lc3b, Slc7a11, Slc40a1, Tfrc, and Slc39a14) were altered after hemin treatment. In addition, analysis of the data retrieved from the GO database for the ten targeted genes showed that 20 items on biological processes, 17 items on cellular components, and 19 items on molecular functions were significantly enriched. Based on the GO data, we performed GSEA and found that the glutathione metabolic process was significantly enriched in the hemin phenotype. Notably, the expression of glutathione S-transferase omega (GSTO2), which is involved in glutathione metabolism, was decreased after hemin treatment, and overexpression of Gsto2 decreased lipid reactive oxygen species level in hemin-exposed HT22 cells. In addition, the expression of GSTO2 was also decreased in a mouse model of hippocampus-intracerebral hemorrhage (h-ICH). The decreased expression of GSTO2 in the glutathione metabolic process may be involved in ferroptotic neuronal injury following hemorrhagic stroke.
DOCIVYX Injection (10 mg/mL) requires NO prior dilution with a diluent and is ready to add to the infusion solution. Use only a 21-gauge needle to withdraw DOCIVYX from the vial because larger bore needles (e.g., 18 and 19 gauge) may result in stopper coring and rubber particulates.

  1. DOCIVYX vials should be stored between 2°C and 25°C (36°F and 77°F). If the vials are stored under refrigeration, allow the appropriate number of vials of DOCIVYX vials to stand at room temperature for approximately 5 minutes before use.
  2. Using only a 21-gauge needle, aseptically withdraw the required amount of DOCIVYX Injection (10 mg docetaxel/mL) with a calibrated syringe and inject via a single injection (one shot) into a 250 mL infusion bag or bottle of either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to produce a final concentration of 0.3 mg/mL to 0.74 mg/mL.
  3. If a dose greater than 200 mg of DOCIVYX is required, use a larger volume of the infusion vehicle so that a concentration of 0.74 mg/mL DOCIVYX is not exceeded.
  4. Thoroughly mix the infusion by gentle manual rotation.
  5. As with all parenteral products, DOCIVYX should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit. If the DOCIVYX final infusion solution is not clear or appears to have precipitation, it should be discarded.
  6. DOCIVYX final infusion solution is supersaturated, therefore may crystallize over time. If crystals appear, the solution must no longer be used and shall be discarded.



The DOCIVYX final infusion solution should be administered intravenously as a 1-hour infusion under ambient room temperature (below 25°C) and lighting conditions.
Patients will use the New Voice Prosthesis for two weeks to investigate short term feasibility and explore limitations and advantages. If the patient wishes to leave the New Voice Prosthesis in situ, this will be allowed under the condition that the subject agrees to remain in the study and report (adverse) events on an ongoing basis, until the device is removed after a maximum of 12 months.
Disclosed is a consumer product comprising a plurality of microcapsules dispersed in a dispersing medium. The microcapsules comprise a core and a shell around the core. The core comprises at least one functional material. The shells of the microcapsules are coated with chitosan. The dispersing medium comprises additional free chitosan. Disclosed is also a method for making such a consumer product, a method for enhancing the deposition and rinse resistance of a plurality of microcapsules dispersed in a dispersing medium and a use of chitosan for enhancing the deposition and rinse resistance of a plurality of microcapsules dispersed in a dispersing medium.
Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
Basic studies suggested that sympathetic nerves over-activity played an important role in the pathophysiological changes of arrhythmia occurrence. Present studies of renal ablation show a new method to decrease sympathetic nerves activity. Circumferential pulmonary vein isolation (CPVI) is an accepted ablation method for atrial fibrillation. The investigators plan to evaluate the efficiency and safety of CPVI plus renal sympathetic modification for atrial fibrillation ablation comparing with CPVI alone. The trial is going to recruit 100 patients randomized into two groups (CPVI+RSM group VS CPVI group = 50:50) with a follow-up duration of 4 years. The investigators aim to observe the relapse of atrial tachyarrhythmia lasting more than 30 seconds, the incidence of composite cardiovascular events after renal sympathetic modification, and safety and efficacy of the intervention, comparing with CPVI alone.
BACKGROUND: Skin cancer, a prevalent form of cancer that is on the rise worldwide, requires proactive prevention strategies to reduce the burden of screening, treatment, and mortality. The KEGG research highlighted the significant involvement of red module genes in protein digestion and absorption. These findings provide valuable insights into the underlying molecular mechanisms associated with skin cancer susceptibility, offering potential targets for further research and development of preventive strategies.
MATERIALS AND METHODS: Hub genes numbered 130. "limma" in R found 600 DEGs from GSE66359 dataset. DEGs are enriched in BP: chromosome segregation, CC: chromosomal region, and MF: DNA replication origin binding, according to GO analysis. Cell cycle was enriched in DEGs by KEGG and GSEA. Finally, significant genes were COL5A1, CTHRC1, ECM1, FSTL1, KDELR3, and WIPI1.
RESULTS: ECM1 and WIPI1 greatly prevented skin cancer. This study created a coexpression network using WGCNA to investigate skin cancer susceptibility modules and cardiovascular disease genes.
CONCLUSION: Our study finds a module and many important genes that are essential building blocks in the etiology of skin cancer, which may help us understand the molecular mechanisms of disease prevention.
Total knee arthroplasty (TKA) is one of the most commonly performed orthopaedic surgeries worldwide and has proven to be a success in the treatment of end-stage osteoarthritic knees. TKA is associated with significant postoperative pain which may delay the patient's functional recovery and necessitate an increased use of opioid analgesias, which are themselves associated with significant adverse effects such as nausea and vomiting. The selective cycloxygenase (COX)-2 inhibitor rofecoxib was previously shown in a clinical trial in a paper by Buvanendran et al to reduce postoperative opioid requirement and improve clinical outcomes. Feng et al studied the use of a single dose of rofecoxib pre-operatively and its effect on inflammatory markers and postoperative pain. Rofecoxib has, however, been withdrawn from the market due to its association with cardiovascular side effects. Our current clinical practice in post-operative pain management constitutes post-operative etoricoxib but we hypothesize that pre-emptively administering etoricoxib pre-operatively would give an even greater benefit in terms of post-operative opioid usage, pain scores, and functional recovery in the first 2-3 days. To date, there has been no study investigating etoricoxib as a pre-emptive medication in patients undergoing total knee arthroplasty. We aim to conduct a study to test the efficacy of pre-emptive etoricoxib in reducing postoperative pain, opioid requirement and improving the rate of functional recovery.
The invention provides a detection method of agrimony and a preparation method and a quality control method of formula granules of the agrimony, which solve the problem of inconsistent content of main components between the formula granules of the agrimony and traditional Chinese medicine standard decoction. The quality control method of the hairyvein agrimony formula particles comprises the step of obtaining a characteristic map of the hairyvein agrimony formula particles, wherein the characteristic map at least comprises chromatographic peaks corresponding to protocatechuic acid, ellagic acid, isoquercitrin, quercitrin and quercetin. The characteristic peaks of protocatechuic acid, ellagic acid, isoquercitrin, quercitrin and quercetin are respectively peak 1-peak 5, the characteristic spectrum also includes peak 6, the peak of quercetin is used as reference peak S  2  Peak 6 and reference peak S  2  The relative retention time of (a) is 1.02. + -. 0.1. The invention realizes the common control of active ingredients such as flavonoids, phenolic acids and the like, realizes the integral quality control of the agrimony formula particles, and achieves the effects of accurately, objectively and effectively controlling the quality of the agrimony formula particles and ensuring the effectiveness of clinical medication.
Intervention: Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word "stevia" refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet.
PURPOSE:To produce amorphous calcium phosphate having excellent biocompatibility and having physical properties similar to those of bone tissue, by reacting a Ca salt with PO4, and filtering and drying the reaction product at a low temperature. CONSTITUTION:A reaction product obtained by the reaction of a Ca salt [e.g. Ca(NO3)2] with a PO4 salt [e.g. (NH4)3PO4] in an aqueous medium at 10-12pH is filtered at -10-0 deg.C, and is freeze-dried to obtain amorphous calcium phosphate [Ca3(PO4)2.xH2O]. The obtained amorphous calcium phosphate is added to an aqueous solution containing 10-60wt% curing agents selected from glycolic acid, lactic acid, glutamic acid, pantotheic acid, acrylic acid, their polymers, and a copolymer of the acids and <=10wt% carboxylic acid. A bio-compatible composition suitable as a filler for filling the gap of a dental groove, a restoration material for alveolar bone, etc. can be produced by this process.
Participants receive paclitaxel 175 mg/m\^2 intravenously (IV) or docetaxel 75 mg/m\^2 IV or vinflunine 320 mg/m\^2 IV, on Day 1 of each 3-week cycle (Q3W). Eligible participants who experience disease progression may be able to switch over to receive pembrolizumab 200 mg Q3W for up to 35 treatment administrations (up to approximately 2 years).
PURPOSE: A process of stabilizing lecithin at room temperature for a long period time by mixing lecithin with tocopherol derivatives is provided. Therefore, the stabilizing process does not need separate purifying and separating processes, the mixed composition of lecithin and tocopherol derivatives can be included in foods, cosmetics, drugs or the like. CONSTITUTION: A tocopherol derivative of formula(I) is added to lecithin in a ratio of 0.01 to 5.0 times, based on the total weight of lecithin. In formula, R1, R2 and R3 are H or methyl, at least one of R1, R2 and R3 is methyl, A is CH2-CH(CH3)- or CH=C(CH3)-. For an example, 9.87g phosphorous oxychloride is dissolved in 10ml THF and added with a mixture of 21.54g α-tocopherol, 6.10g triethylamine and 40mg THF to produce tocopherol dichlorophosphate. Then the tocopherol dichlorophosphate is added with a mixture 3.76g 3-amino-1-propanol, 11.11g triethanolamine and 20ml THF for 1hr to produce 2-tocopherol tetrahydro-2H-1,3,2-oxazaphosphorine P-oxide. The 2-tocopherol tetrahydro-2H-1,3,2-oxazaphosphorine P-oxide is added with hydrocholic acid and agitated after removing triethylammonium chloride to produce 25g 3-aminopropyl-α-tocopherol phosphate.
This invention relates to compositions and methods useful for activating LT.beta. receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-.alpha. and multiple subunits of lymphotoxin-.beta., which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-.beta. receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-.beta. receptor which act as lymphotoxin-.beta. receptor activating agents alone or in combination with other lymphotoxin-.beta. receptor activating agents either in the presence or absence of lymphotoxin.alpha./.beta. complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using crosslinked anti-lymphotoxin-.beta. receptor antibodies either alone or in the presence of other lymphotoxin-.beta. receptor activating agents to potentiate tumor cell cytotoxicity.
The invention relates to the veterinary field. Proposed is a method for temporary blocking sexual function in a male mammal including behavioural phenomena (search for a partner, vocalization, etc.). The method comprises administration of a pharmaceutical composition once or twice to an animal, wherein said composition comprises the following active ingredients: an α-adrenergic blocking agent, tropic to the posterior nucleus of the hypothalamus, melatonin, and a steroid with gestagenic activity. The method makes it possible, while using the minimal dose of the steroid hormone, to inhibit sexual behaviour of a male animal for the period of several weeks to half a year (depending on the length of the daytime period). The pharmaceutical composition is intended for transdermal administration during any period of the sexual cycle. The use of the drug preparation is not associated with any side effects characteristic of the drugs of this type.